1
|
Ozbey AC, Combarel D, Poinsignon V, Lovera C, Saada E, Mir O, Paci A. Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC. Pharmaceuticals (Basel) 2021; 14:ph14090927. [PMID: 34577627 PMCID: PMC8469080 DOI: 10.3390/ph14090927] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 09/05/2021] [Accepted: 09/09/2021] [Indexed: 11/16/2022] Open
Abstract
Pazopanib is a potent multi-targeted kinase inhibitor approved for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. The pharmacokinetics of pazopanib is characterized by a significant inter- and intra-patient variability and a target through plasma concentration of 20.5 mg·L-1. However, routine monitoring of trough plasma concentrations at fixed hours is difficult in daily practice. Herein, we aimed to characterize the pharmacokinetic (PK) profile of pazopanib and to identify a target area under the curve (AUC) more easily extrapolated from blood samples obtained at various timings after drug intake. A population pharmacokinetic (popPK) model was constructed to analyze pazopanib PK and to estimate the pazopanib clearance of a patient regardless of the time of sampling. Data from the therapeutic drug monitoring (TDM) of patients with cancer at Institute Gustave Roussy and a clinical study (phase I/II) that evaluates the tolerance to pazopanib were used. From the individual clearance, it is then possible to obtain the patient's AUC. A target AUC for maximum efficacy and minimum side effects of 750 mg·h·L-1 was determined. The comparison of the estimated AUC with the target AUC would enable us to determine whether plasma exposure is adequate or whether it would be necessary to propose therapeutic adjustments.
Collapse
Affiliation(s)
- Agustos Cetin Ozbey
- Service de Pharmacologie, Département de Biologie et Pathologie Médicales, Gustave Roussy, Université Paris-Saclay, F-94800 Villejuif, France; (A.C.O.); (D.C.); (V.P.)
| | - David Combarel
- Service de Pharmacologie, Département de Biologie et Pathologie Médicales, Gustave Roussy, Université Paris-Saclay, F-94800 Villejuif, France; (A.C.O.); (D.C.); (V.P.)
- Service de Pharmacocinétique, Faculté de Pharmacie, Université Paris-Saclay, F-92296 Chatenay-Malabry, France
| | - Vianney Poinsignon
- Service de Pharmacologie, Département de Biologie et Pathologie Médicales, Gustave Roussy, Université Paris-Saclay, F-94800 Villejuif, France; (A.C.O.); (D.C.); (V.P.)
| | - Christine Lovera
- Centre Antoine Lacassagne, Délégation à la Recherche Clinique, F-06189 Nice, France; (C.L.); (E.S.)
| | - Esma Saada
- Centre Antoine Lacassagne, Délégation à la Recherche Clinique, F-06189 Nice, France; (C.L.); (E.S.)
| | - Olivier Mir
- Département de Soins Ambulatoire, Gustave Roussy, F-94800 Villejuif, France;
| | - Angelo Paci
- Service de Pharmacologie, Département de Biologie et Pathologie Médicales, Gustave Roussy, Université Paris-Saclay, F-94800 Villejuif, France; (A.C.O.); (D.C.); (V.P.)
- Service de Pharmacocinétique, Faculté de Pharmacie, Université Paris-Saclay, F-92296 Chatenay-Malabry, France
- Correspondence:
| |
Collapse
|
2
|
Mir O, Penel N. Targeting angiogenesis in advanced soft tissue sarcoma: tivozanib-hype or me-too? Ann Oncol 2019; 28:13-15. [PMID: 28177430 DOI: 10.1093/annonc/mdw631] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Affiliation(s)
- O Mir
- Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif
| | - N Penel
- Methodology and Clinical Research Platform, SIRIC OncoLille, Lille, France
| |
Collapse
|
3
|
Bellesoeur A, Boudou-Rouquette P, Thomas-Schoemann A, Joly C, Tlemsani C, Vidal M, Goldwasser F, Blanchet B. Individualized Pazopanib Dosing-Letter. Clin Cancer Res 2017; 23:6377. [PMID: 29030334 DOI: 10.1158/1078-0432.ccr-17-1873] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Accepted: 07/27/2017] [Indexed: 11/16/2022]
Affiliation(s)
- Audrey Bellesoeur
- Department of Medical Oncology, Hôpital Cochin, AP-HP, Paris, France.,Université Paris Descartes, Paris, France.,CARPEM, Paris, France
| | - Pascaline Boudou-Rouquette
- Department of Medical Oncology, Hôpital Cochin, AP-HP, Paris, France.,Université Paris Descartes, Paris, France.,CARPEM, Paris, France
| | - Audrey Thomas-Schoemann
- Department of Pharmacokinetics and Pharmacochemisty, Hôpital Cochin, AP-HP, Paris, France. .,CARPEM, Paris, France
| | - Charlotte Joly
- Department of Medical Oncology, Hôpital Henri Mondor, AP-HP, Paris, France
| | - Camille Tlemsani
- Department of Medical Oncology, Hôpital Cochin, AP-HP, Paris, France.,Université Paris Descartes, Paris, France.,CARPEM, Paris, France
| | - Michel Vidal
- Department of Pharmacokinetics and Pharmacochemisty, Hôpital Cochin, AP-HP, Paris, France.,CARPEM, Paris, France
| | - François Goldwasser
- Department of Medical Oncology, Hôpital Cochin, AP-HP, Paris, France.,Université Paris Descartes, Paris, France.,CARPEM, Paris, France
| | - Benoit Blanchet
- Department of Pharmacokinetics and Pharmacochemisty, Hôpital Cochin, AP-HP, Paris, France.,CARPEM, Paris, France
| |
Collapse
|